Interrompre un traitement par analogues du GLP-1 comme l’Ozempic érode rapidement les bénéfices cardiovasculaires protecteurs, augmentant le risque d’accidents cardiaques chez les patients diabétiques tout en entraînant une reprise pondérale et une détérioration des paramètres métaboliques, selon une étude menée par une équipe de l’Université Washington à Saint-Louis et publiée en mars 2026 dans BMJ Medicine.
Washington University Study Tracks 333,687 Diabetic Veterans
For years, clinical tracking of glucagon-like peptide-1 receptor agonists—the class of medications that includes Ozempic—focused heavily on the immediate cardiovascular benefits experienced while patients actively took the drugs. A team of researchers at Washington University in Saint-Louis sought to answer what happens after prescriptions stop. Published in BMJ Medicine, their investigation examined the medical trajectories of 333,687 diabetic veterans. Within this cohort, 132,551 patients received GLP-1 receptor agonists, while 201,136 served as a control group taking older diabetes medications.
Patients who maintained an uninterrupted three-year regimen of GLP-1 therapies demonstrated roughly an 18% reduction in cardiovascular events. This translated to approximately four avoided events for every one hundred patients treated. However, stopping the injections reversed these protective gains. Patients who spent one year off the medication faced a 14% higher risk of cardiovascular incidents compared to those who maintained strict adherence. That heightened risk expanded to 22% for individuals who discontinued treatment for two years.
In Plain English: The Clinical Takeaway
- GLP-1 Receptor Agonists: A class of medications, including Ozempic.
- Cardiovascular Protection: The reduction in cardiovascular accidents provided by continuous medication use, which diminishes rapidly once treatment ceases.
- Metabolic Rebound: The physiological return of inflammation, high blood pressure, and elevated cholesterol after stopping effective drug therapy.
Cardiovascular Protection Erodes Within Six Months of Discontinuation
The study revealed that duration dictates success in both directions. While continuous use for at least two years was required to secure measurable cardiovascular advantages, an interruption as short as six months was enough to reverse the trend. Nearly one in four study participants had stopped their treatment entirely, and a similarly large proportion had suspended their injections for more than six months before eventually returning to the regimen.
Restarting the medication after a prolonged pause failed to reset the baseline to zero. Patients who interrupted and later resumed their injections recovered an average risk reduction of only 12%, compared to the 18% benefit observed in the most compliant users. A six-month gap left a residual excess risk of 4% to 8% when compared directly against patients who never missed a dose. The data indicates that the longer a treatment pause extends, the more difficult those lost therapeutic gains become to recover.
| Treatment Status & Duration | Cardiovascular Risk Impact | Observed Benefit |
|---|---|---|
| Continuous Use (3 Years) | -18% Risk | ~4 events avoided per 100 patients |
| Discontinued for 1 Year | +14% Risk | Protection eroded compared to adherent peers |
| Discontinued for 2 Years | +22% Risk | Significant loss of cardiovascular protection |
| Interrupted then Resumed | -12% Risk | Reduced efficacy compared to uninterrupted use |
Metabolic Regrowth and Weight Regain Follow Drug Cessation
Beyond the heart, stopping Ozempic triggered a return of lost weight and a dismantling of metabolic progress. Inflammation markers began trending upward, alongside increases in blood pressure and cholesterol levels. Ziyad Al-Aly, who piloted the study at Washington University, noted that public enthusiasm surrounding these molecules frequently overlooks what happens when individuals stop taking them. « On se passionne pour le démarrage des GLP-1, sans prêter assez d’attention à ce qui se passe quand les gens arrêtent », stated Al-Aly.
While the study relied primarily on a predominantly male cohort of military veterans, the findings serve as an association rather than direct proof of absolute cause and effect. Yet, the data highlights the necessity of viewing these therapies as foundational, long-term treatments rather than short-term interventions that can be suspended on a whim. The researchers advocate for structured, supervised tapering programs rather than abrupt cessation, while calling for subsequent clinical investigations across more diverse patient populations.
Contraindications & When to Consult a Doctor
Patients diagnosed with type 2 diabetes must not discontinue prescribed GLP-1 receptor agonist therapies independently. Abrupt cessation can trigger metabolic rebound and accelerated loss of cardioprotective benefits. Consult a physician before making any adjustments to a long-term medication schedule.
References
- BMJ Medicine: Association of GLP-1 receptor agonist discontinuation with cardiovascular outcomes in patients with type 2 diabetes.
- Washington University in Saint-Louis: Clinical epidemiology research on veteran health records.
